Experienced in Grover's Disease

Dr. Boni E. Elewski

University Of Alabama Health Services Foundation, PC
Birmingham, AL
Experienced
in Grover's Disease
Specialties:Dermatology
Accepting New Patients
47 Years of Experience
OverviewInsuranceLocationsClinical Research

Overview

Boni Elewski is a Dermatologist in Birmingham, Alabama. Dr. Elewski has been practicing medicine for over 47 years and is rated as an Experienced provider by MediFind in the treatment of Grover's Disease. Her top areas of expertise are Ringworm, Psoriasis, Plaque Psoriasis, and Generalized Pustular Psoriasis (GPP). Dr. Elewski is currently accepting new patients.

Her clinical research consists of co-authoring 164 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
1978
Specialties
Dermatology
Licenses
Dermatology in AL
Hospital Affiliations
University Of Alabama Hospital
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield

Locations

UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION, PC
619 19th St S, Birmingham, AL 35249
205-934-4011

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis
An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis
Enrollment Status: Completed
Publish Date: December 15, 2023
Intervention Type: Drug
Study Drug: Metaderm
Study Phase: Phase 4
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis
A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis
Enrollment Status: Completed
Publish Date: October 29, 2021
Intervention Type: Drug
Study Phase: Phase 4
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
Dietary Prevention of Photodamage in Skin With Grapes: A Human Clinical Study
Dietary Prevention of Photodamage in Skin With Grapes: A Human Clinical Study
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Other
Study Phase: Not Applicable
View 9 Less Clinical Trials

165 Total Publications

CD2 expressing innate lymphoid and T cells are critical effectors of immunopathogenesis in hidradenitis suppurativa.
CD2 expressing innate lymphoid and T cells are critical effectors of immunopathogenesis in hidradenitis suppurativa.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: November 19, 2024
Similar Doctors
Expertise in
15
conditions
Dr. Rebecca B. Kissel
Dermatology
Expertise in
15
conditions
Dr. Rebecca B. Kissel
Dermatology

University Of Alabama Health Services Foundation, PC

619 19th St S, 
Birmingham, AL 
205-934-4011
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rebecca Kissel is a Dermatologist in Birmingham, Alabama. Dr. Kissel and is rated as a Distinguished provider by MediFind in the treatment of Grover's Disease. Her top areas of expertise are Hidradenitis Suppurativa, Actinic Keratosis, Warts, and Grover's Disease. Dr. Kissel is currently accepting new patients.

Expertise in
6
conditions
Dr. Lauren C. Kole
Dermatology
Expertise in
6
conditions
Dr. Lauren C. Kole
Dermatology

University Of Alabama Health Services Foundation, PC

619 19th St S, 
Birmingham, AL 
205-934-4011
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Lauren Kole is a Dermatologist in Birmingham, Alabama. Dr. Kole and is rated as an Advanced provider by MediFind in the treatment of Grover's Disease. Her top areas of expertise are Hidradenitis Suppurativa, Psoriasis, Actinic Keratosis, and Atopic Dermatitis. Dr. Kole is currently accepting new patients.

Expertise in
6
conditions
Dr. Peter G. Pavlidakey
Dermatology
Expertise in
6
conditions
Dr. Peter G. Pavlidakey
Dermatology

University Of Alabama Health Services Foundation, PC

619 19th St S, 
Birmingham, AL 
205-934-4011
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Peter Pavlidakey is a Dermatologist in Birmingham, Alabama. Dr. Pavlidakey and is rated as an Advanced provider by MediFind in the treatment of Grover's Disease. His top areas of expertise are Melanoma, Cutis Gyrata Syndrome, Bowen's Disease, and Basal Cell Skin Cancer. Dr. Pavlidakey is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile